The latest market report published by Credence Research, Inc. “CAR T Cell Therapy Market – Growth, Future Prospects, Competitive Analysis, 2018 – 2026,” the global CAR T cell therapy market is expected to expand at a CAGR of 5.96 % from 2018 to 2026.

Browse the full report CAR T Cell Therapy Market – Growth, Future Prospects, Competitive Analysis, 2018 – 2026 report at http://www.credenceresearch.com/report/car-t-cell-therapy-market

Market Insights

The diagnosis of acute lymphocytic leukemia (ALL) is very ambiguous as the symptoms overlap with Non-Hodgkin lymphoma. Due to technological advancement in the diagnostic kits acute lymphocytic lymphoma can be detected early and effective treatment can be started immediately. Flow cytometry and immunohistochemistry are useful in identifying the immunophenotyping by the proteins expressed by the cells. It is useful in determining the exact type of leukemia. Chromosome testing is being widely employed for the precise diagnosis of acute lymphocytic leukemia to accurately identify the DNA translocation between chromosome 9 and chromosome 22. World Health organization guidelines have postulated that acute lymphocytic leukemia can be prevented upto a certain extent by prohibiting the exposure to radiation, chemical, viral infection, cigarette smoking and prolonged exposure to gasoline and electromagnetic fields. The traditional approach adopted for the treatment of ALL was blood transfusion to increase the count of healthy blood cells, antibiotics used to curb the spread of infection and chemotherapy to kill the leukemia cells present in the bone marrow. CAR T cell therapy is the most hot topic discussed among oncologist throughout the globe. The FDA approved CAR T cell therapy are Axicabtagene ciloleucel (Yescarta), Tisagenleucel (Kymriah), and Tocilizumab (Actemra). During the clinical trial studies few side effects have been encountered in patients put on CAR T cell therapy are cytokine release syndrome, b-cell aplasia and tumor lysis syndrome.

Currently CD19 antigens have been approved by USFDA for the treatment of relapsed b-cell acute lymphocytic leukemia. CD 22 and CD 30 antigens show promising result in preclinical trials for the treatment of non-Hodgkin’s lymphoma.

Recent approval of CD19 antigens as CAR T cell therapy for the treatment of b cell acute lymphocytic leukemia and increasing number of children suffering with acute lymphocytic leukemia is responsible for the dominance of ALL.  Non-Hodgkin’s lymphoma and multiple myeloma are being diligently studied by pharmaceutical players owing to their rising prevalence and lack of efficacy utilizing chemotherapy.

Rising prevalence of relapsed acute lymphocytic leukemia and technological advancement in the screening of cancer drives the North America CAR T cells therapy market. Moreover the domicile of pharmaceutical companies pioneering in CAR T cell therapy. Increasing geriatric population suffering with leukemia and government initiatives to fight cancer will result in the positive growth of CAR T cell therapy in Asia Pacific.

The major pharmaceutical players actively engaged in the CAR T cell therapy market are Bellicum Pharmaceuticals, Inc., Immune Therapeutics, Celgene Corporation, Cellectis, Kite Pharma, Eureka Therapeutics, Juno Therapeutics, Sorrento Therapeutics and Novartis AG among others.

Key Market Movements:

  • Rising prevalence of patients suffering with relapsed b cell acute lymphocytic leukemia
  • Proactive role adopted by regulatory agencies for the expedited approval of CAR T cell therapy
  • Promising pipeline for CAR T cell therapy focusing on CD22, CD30 antigens for the treatment of non-Hodgkin’s lymphoma and acute myeloid leukemia respectively

Browse the full report CAR T Cell Therapy Market – Growth, Future Prospects, Competitive Analysis, 2018 – 2026 report at http://www.credenceresearch.com/report/car-t-cell-therapy-market

 

Latest Reports:

Threat Intelligence Market: http://www.credenceresearch.com/press/global-threat-intelligence-market

 

CAR T-Cells can be either autologous; meaning they are derived from the blood of the patient themselves, or allogenic; meaning that they are derived from the blood of a healthy donor. These T-Cells are genetically engineered to express a CAR. These CAR T-Cells are programmed to target antigens that are present on the surface of tumours. When they come in contact with the antigens on the tumours, the CAR T-Cells are activated via the signal peptide and become cytotoxic. They do all of this independently from the major histocompatibility complex (MHC)[3] The CAR T-cells destroy the cancer cells through mechanisms such as extensive stimulated cell proliferation, increasing the degree to which the cell is toxic to other living cells i.e. cytotoxicity, and by causing the increased production of factors that are secreted from cells in the immune system that have an effect on other cells in the organism. These factors are called cytokines and include interleukins, interferons and growth factors.

Source: Wikipedia

 

CAR T-Cell Therapy Where are We Today?

CAR T-cell therapy has been generating remarkable results in the fight to cure cancer. The development of this cell-based therapy from the lab to the clinic hasn’t all been smooth sailing, however. Serious side effects and even deaths have occurred in some clinical trials. These tragic set-backs have prompted a great deal of caution and vigilance in the field. Overall, though, there is still great optimism. CAR T-cell trials have yielded impressive results in the treatment of blood cancers such as leukemia and B cell lymphoma. In certain studies, for example, up to 90 percent of children and adults with an “untreatable” acute form of leukemia achieved remission after receiving CAR T-cell therapy. Each successive generation of CAR T-cell products has sought to minimize complications while maximizing the effectiveness of treatment.  [Ref: medcision.com]

 

About:
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared for this task.

Media Contact
Name: Chris Smith
Address: 105 N 1st ST #429
SAN JOSE, CA 95103 US
E-mail: sales@credenceresearch.com
Ph: 1-800-361-8290
Web: http://www.credenceresearch.com